BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 34859284)

  • 1. Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC.
    Ribback S; Winter S; Klatte T; Schaeffeler E; Gellert M; Stühler V; Scharpf M; Bedke J; Burchardt M; Schwab M; Lillig CH; Kroeger N
    World J Urol; 2022 Mar; 40(3):739-746. PubMed ID: 34859284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LZTS2: A novel and independent prognostic biomarker for clear cell renal cell carcinoma.
    Peng Y; Greenland NY; Lang UE; Stohr BA
    Pathol Res Pract; 2022 Apr; 232():153831. PubMed ID: 35287088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.
    Liu J; Liu Z; Liu Q; Li L; Fan X; Wen T; An G
    Oncol Rep; 2018 Oct; 40(4):2023-2035. PubMed ID: 30066941
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lin W; Chen X; Chen T; Liu J; Ye Y; Chen L; Qiu X; Chia-Hsien Cheng J; Zhang L; Wu J; Qiu S
    DNA Cell Biol; 2020 Jun; 39(6):1000-1011. PubMed ID: 32282241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thioredoxin 1 as a subcellular biomarker of redox imbalance in human prostate cancer progression.
    Shan W; Zhong W; Zhao R; Oberley TD
    Free Radic Biol Med; 2010 Dec; 49(12):2078-87. PubMed ID: 20955789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma.
    Saeednejad Zanjani L; Madjd Z; Axcrona U; Abolhasani M; Rasti A; Asgari M; Fodstad Ø; Andersson Y
    Ann Diagn Pathol; 2020 Jun; 46():151483. PubMed ID: 32143173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thioredoxin-1 redox signaling regulates cell survival in response to hyperoxia.
    Floen MJ; Forred BJ; Bloom EJ; Vitiello PF
    Free Radic Biol Med; 2014 Oct; 75():167-77. PubMed ID: 25106706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Serine Peptidase Inhibitor Kazal Type 13 (SPINK13) as a Clinicopathological and Prognostic Biomarker in Patients with Clear Cell Renal Cell Carcinoma.
    Xu WH; Shi SN; Wang J; Xu Y; Tian X; Wan FN; Cao DL; Qu YY; Zhang HL; Ye DW
    Med Sci Monit; 2019 Dec; 25():9458-9470. PubMed ID: 31825950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating HECW1 expression into the clinical indicators exhibits high accuracy in assessing the prognosis of patients with clear cell renal cell carcinoma.
    Wang C; Dong K; Wang Y; Peng G; Song X; Yu Y; Shen P; Cui X
    BMC Cancer; 2021 Aug; 21(1):890. PubMed ID: 34348693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of immunohistochemical staining for myoferlin in clear cell renal cell carcinoma and its association with epidermal growth factor receptor expression.
    Jung M; Lee C; Park JH; Moon KC
    Urol Oncol; 2019 Nov; 37(11):812.e9-812.e16. PubMed ID: 31421995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
    Rabjerg M
    Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synchronous Metastatic Clear-Cell Renal Cell Carcinoma: A Distinct Morphologic, Immunohistochemical, and Molecular Phenotype.
    Kammerer-Jacquet SF; Brunot A; Pladys A; Bouzille G; Dagher J; Medane S; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Edeline J; Laguerre B; Lespagnol A; Mosser J; Dugay F; Belaud-Rotureau MA; Rioux-Leclercq N
    Clin Genitourin Cancer; 2017 Feb; 15(1):e1-e7. PubMed ID: 27444986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Identification of Zinc-Finger Protein 433 as a Possible Prognostic Biomarker for Clear-Cell Renal Cell Carcinoma.
    Heyliger SO; Soliman KFA; Saulsbury MD; Reams RR
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
    Schultz L; Chaux A; Albadine R; Hicks J; Kim JJ; De Marzo AM; Allaf ME; Carducci MA; Rodriguez R; Hammers HJ; Argani P; Reuter VE; Netto GJ
    Am J Surg Pathol; 2011 Oct; 35(10):1549-56. PubMed ID: 21881486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The thioredoxin system in breast cancer cell invasion and migration.
    Bhatia M; McGrath KL; Di Trapani G; Charoentong P; Shah F; King MM; Clarke FM; Tonissen KF
    Redox Biol; 2016 Aug; 8():68-78. PubMed ID: 26760912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of amyloid A immunoexpression in the prognosis of renal cell carcinoma.
    Oz Atalay F; Aytac Vuruskan B; Vuruskan H
    APMIS; 2016 Apr; 124(4):257-62. PubMed ID: 26750935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DKC1 serves as a potential prognostic biomarker for human clear cell renal cell carcinoma and promotes its proliferation, migration and invasion via the NF‑κB pathway.
    Zhang M; Pan Y; Jiang R; Hou P; Shan H; Chen F; Jiang T; Bai J; Zheng J
    Oncol Rep; 2018 Aug; 40(2):968-978. PubMed ID: 29901172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation and prognostic significance of manganese superoxide dismutase in clear cell renal cell carcinoma.
    Zhao Z; Lu J; Qu H; Wang Z; Liu Q; Yang X; Liu S; Ge J; Xu Y; Li N; Yuan Y
    Hum Pathol; 2018 Oct; 80():87-93. PubMed ID: 29935195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic implications of Aquaporin 9 expression in clear cell renal cell carcinoma.
    Xu WH; Shi SN; Xu Y; Wang J; Wang HK; Cao DL; Shi GH; Qu YY; Zhang HL; Ye DW
    J Transl Med; 2019 Nov; 17(1):363. PubMed ID: 31703694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma.
    Glaser ZA; Love HD; Guo S; Gellert L; Chang SS; Herrell SD; Barocas DA; Penson DF; Cookson MS; Clark PE
    Urol Oncol; 2017 May; 35(5):286-293. PubMed ID: 28108243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.